Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 9Breast Neoplasms 6Lymphoma, B-Cell, Marginal Zone 4Barrett Esophagus 4Lymphoma, Large B-Cell, Diffuse 3Inflammation 3Head and Neck Neoplasms 3Zollinger-Ellison Syndrome 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Lymphoma 2Colorectal Neoplasms 2Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Stomach Ulcer 1Solid Tumours 1Solid Tumor 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Prostate Cancer Patients 1Precancerous Gastric Lesions 1Pharmacokinetics of MDV3100 1Peripheral Nervous System Diseases 1Ovarian Neoplasms 1Obesity 1Mouth Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

vorasidenib 1repaglinide 1Rosuvastatin Calcium 1Omeprazole 1Midazolam 1Flurbiprofen 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Healthy Adult Participants × Omeprazole × Clear all
NCT07235748 2026-02-17

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants

Servier

Phase 1 Completed
28 enrolled

Healthy Adult Participants

Data powered by HemOnc (CC BY 4.0) Colophon âš¡